For patients with high-risk soft tissue sarcoma, surgery remains a cornerstone of treatment, but the risk of recurrence continues to be a major clinical challenge. Researchers are investigating whether combining immunotherapy with radiotherapy before surgery can improve long-term outcomes.
Immutep reported that 12-month disease-free survival (DFS) was 81.1% among 38 patients who underwent surgery in the Phase II EFTISARC-NEO study. The investigator-initiated trial is evaluating eftilagimod alfa, pembrolizumab, and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma.
The survival analysis was presented in a poster (P 448 ) at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, expanding on findings first disclosed in the November 11 abstract. The poster also reported exploratory analyses linking features of the tumor at resection with subsequent disease-free survival. Follow-up is ongoing, and the 18-month DFS estimate remains immature.
Marc Voigt, CEO of Immutep, said:
“With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response.”
How EFTISARC NEO Evaluates Treatment Before Surgery
EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa in combination with pembrolizumab and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. The study assesses how tumors respond to the regimen by examining tissue removed at surgery and follows patients to track recurrence and survival.
The Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, leads the study. The Polish Medical Research Agency provided the primary grant funding, and Immutep supplies eftilagimod alfa. The trial completed enrollment in January 2025 with 40 patients.
The primary endpoint was pathological response, measured as the percentage of tumor tissue showing hyalinization and fibrosis at resection. Immutep previously reported that the study met this endpoint, with median tumor hyalinization and fibrosis of 51.5% after neoadjuvant treatment.
Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response, and health-related quality of life. The November 19 update focused on survival and exploratory associations with tumor tissue findings. Immutep did not report new adverse event rates in that update.
Eftilagimod Alfa in the EFTISARC-NEO Trial
Eftilagimod alfa, also known as efti, is an investigational immunotherapy that activates antigen-presenting cells through the MHC class II pathway. These cells help prime CD8-positive T cells to recognize tumor antigens. In the Phase II EFTISARC-NEO trial, investigators combined eftilagimod alfa with pembrolizumab and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma.
The trial used tissue removed at surgery to assess how tumors responded to the three-part regimen. Median tumor hyalinization and fibrosis was 51.5%, meeting the study’s primary endpoint. In an exploratory analysis, 12-month disease-free survival was 95.0% among patients with more than 310 tumor-infiltrating lymphocytes per mm² after treatment and 64.9% among those with lower levels.
The comparison links greater immune cell infiltration with higher disease-free survival in this cohort. The single-arm design limits conclusions about eftilagimod alfa’s individual contribution.
Disease Free Survival After Surgery
EFTISARC-NEO enrolled 40 patients, of whom 38 underwent surgery and were included in the survival analysis. At the April 30, 2026, data cutoff, eight of those 38 patients had experienced disease recurrence. Median follow-up was 19.1 months.
- 12-month disease-free survival was 81.1%, which Immutep described as mature.
- 18-month disease-free survival was 81.1% by Kaplan-Meier estimation. The company described this estimate as immature.
- 12-month local recurrence-free survival was 94.1%.
- 12-month distant metastasis-free survival was 86.2%.
The recurrence count reflects the events observed by the cutoff, while the percentages estimate outcomes at specific time points. The reported survival estimates come from the surgical cohort receiving the combination regimen. Immutep’s update provided no comparator results or hazard ratios.
Tumor Findings Associated With Disease Free Survival
The CTOS poster examined whether findings in tumor tissue after neoadjuvant treatment were associated with DFS. The analysis evaluated tumor-infiltrating lymphocytes, which are immune cells found within the tumor, and the extent of treatment-related hyalinization and fibrosis, the tissue changes used to assess pathological response in the trial.
- Tumor-infiltrating lymphocytes. Twelve-month DFS was 95.0% in patients with post-treatment levels above 310 cells/mm² and 64.9% in patients with lower levels.
- Hyalinization and fibrosis. Twelve-month DFS was 93.8% in patients with treatment-related hyalinization and fibrosis greater than 52% and 71.4% in patients with lower levels.
- Other tumor markers. The presence of tertiary lymphoid structures and baseline expression of PD-L1, LAG-3, and TIGIT did not correlate with survival outcomes in the reported analysis.
These comparisons were exploratory. Immutep interpreted the association between higher lymphocyte infiltration and longer DFS as consistent with the proposed mechanism of eftilagimod alfa. The investigational agent is a soluble LAG-3 protein that activates antigen-presenting cells through the MHC class II pathway, which can support an antitumor T-cell response.
Plans for a Registration Trial
Immutep is preparing a registration-directed trial of eftilagimod alfa before surgery in soft tissue sarcoma, with a target start in the second half of 2027. The timing depends on regulatory discussions, manufacturing timelines, partnering arrangements, and available resources. The company also expects to report additional data from EFTISARC-NEO in 2027 as patient follow-up continues.
You can also read: SU2C-SARC032: Can ctDNA Predict Outcomes After Radiotherapy and Pembrolizumab in Soft Tissue Sarcoma?

